Anti-Dcp2/TDT antibody [EPR25378-93],Abcam,AB288158

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Rat, Human, Mouse

Application

WB, Flow Cyt (Intra), IP

Platform ID

BAB841341693

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-Dcp2/TDT antibody [EPR25378-93]
Cat. No.AB288158
HostRabbit
IsotypeIgG
ReactivityRat, Human, Mouse
ApplicationWB, Flow Cyt (Intra), IP
ClonalityMonoclonal
Clone NumberEPR25378-93
Concentration0.614 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Decapping metalloenzyme that catalyzes the cleavage of the cap structure on mRNAs (PubMed : 12218187, PubMed : 12417715, PubMed : 12923261, PubMed : 21070968, PubMed : 28002401, PubMed : 31875550). Removes the 7-methyl guanine cap structure from mRNA molecules, yielding a 5'-phosphorylated mRNA fragment and 7m-GDP (PubMed : 12486012, PubMed : 12923261, PubMed : 21070968, PubMed : 28002401, PubMed : 31875550). Necessary for the degradation of mRNAs, both in normal mRNA turnover and in nonsense-mediated mRNA decay (PubMed : 14527413). Plays a role in replication-dependent histone mRNA degradation (PubMed : 18172165). Has higher activity towards mRNAs that lack a poly(A) tail (PubMed : 21070968). Has no activity towards a cap structure lacking an RNA moiety (PubMed : 21070968). The presence of a N(6)-methyladenosine methylation at the second transcribed position of mRNAs (N(6),2'-O-dimethyladenosine cap; m6A(m)) provides resistance to DCP2-mediated decapping (PubMed : 28002401). Blocks autophagy in nutrient-rich conditions by repressing the expression of ATG-related genes through degradation of their transcripts (PubMed : 26098573). See full target information DCP2

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.